This study will test the hypothesis that a novel combination of three drugs (sorafenib, sonidegib, and irinotecan), in conjunction with individually optimized doses, can be safely administered and lead to improved clinical outcomes in patients with hepatocellular carcinoma compared to standard of care. The main objective of this study is to establish safe dose ranges for the coadministration of sorafenib, sonidegib, and irinotecan in patients with hepatocellular carcinoma. Furthermore, we will collect data to inform the application of an artificial intelligence/computational approach to individual dosing of combination chemotherapy. Individualization of dosing will be achieved by using Phenotypic Personalized Medicine (PPM) to maximize treatment efficacy in patients with hepatocellular carcinoma, while minimizing toxicity. Drug efficacy will be assessed by measuring plasma circulating tumor DNA (ctDNA). Toxicity will be assessed by quantitating organ injury and patient tolerability. Recommended dosing for future studies will be based on the totality of the data.

Start Date02 Dec 2024

Sponsor / Collaborator

University of Florida

[+1]

ChiCTR2400081793

/ RecruitingNot ApplicableIIT

Sonidegib for Acute ischemic patients with large VEssel occlusion combined with Revascularization (SAVER), a multi-center, prospective, randomized trial

Start Date12 Mar 2024

Sponsor / Collaborator

The Second Military Medical University

ACTRN12623001216606

/ RecruitingPhase 2IIT

Single-institution, single-arm, open-label phase II basket study investigating the effect of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies

Start Date12 Dec 2023

Sponsor / Collaborator

Northern Sydney Local Health District

100 Clinical Results associated with Sonidegib Phosphate

100 Translational Medicine associated with Sonidegib Phosphate

100 Patents (Medical) associated with Sonidegib Phosphate

548

Literatures (Medical) associated with Sonidegib Phosphate

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case report

Article

Author: Yao, Zhijian ; Wei, Gao ; Li, Longshan ; Ruan, Zhuren ; Zhao, Chen ; Li, Xianghui

PURPOSE:

Basal cell carcinoma (BCC) is one of the most common skin cancers. Most BCCs can be treated with surgery excision. For advanced BCC unsuitable for curative surgery, the combination of radiotherapy and Hedgehog pathway inhibitors (HHI) are effective systemic treatment options. However, there is a scarcity of evidence-based guidelines for the management of patients with advanced or metastatic BCC, particularly those who develop resistance to HHI therapy.

MATERIALS AND METHODS:

We report the case of a patient with advanced BCC of the head and neck, which originated from a nevus sebaceous.

RESULTS:

The patient initially responded well to sonidegib, an HHI, but resistance emerged within a month. We then modified the systemic therapy to include a combination of radiotherapy and the anti-PD-1 agent sintilimab.

CONCLUSIONS:

This adjusted treatment regimen led to effective long-term clinical responses without significant adverse events.

04 Apr 2025·ORGANIC LETTERS

3-Oxabicyclo[3.1.1]heptanes as Isosteres of meta-Substituted Benzene Rings

Article

Author: Morvan, Jennifer ; Buijnsters, Peter J. J. A. ; Renders, Evelien ; Ryabchuk, Pavel

Replacement of the aromatic rings in drug candidates with isosteric rigid sp³-rich scaffolds can improve physicochemical properties, increase the chance of progressing the molecule in development, and open new chemical space. Isosteres of meta-substituted benzenes remain challenging due to the difficulty of mimicking the exit vector angles and bond distances. Herein, we report the synthesis of 1,5-disubstituted 3-oxabicyclo[3.1.1]heptanes (oxa-BCHeps), which can serve as saturated isosteres of meta-substituted phenyl rings with a similar geometric arrangement. This structural motif can be obtained under mild reaction conditions via acid-mediated isomerization of (2-oxaspiro[3.3]heptan-6-yl)methanols using catalytic quantities of pyridinium chloride (PyrHCl). We demonstrate the utility of this methodology by preparing various building blocks for use in medicinal chemistry and incorporating 3-oxa-BCHep into the anticancer drug sonidegib, improving its physicochemical properties, such as permeability, metabolic stability, and solubility.

01 Apr 2025·AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Clinicopathologic and Molecular Characterization of Basal Cell Carcinoma Arising at Sun-protected Sites

Article

Author: Hanna, John ; Russell-Goldman, Eleanor ; Draper, Elizabeth ; Mahadevan, Navin R. ; Li, Yvonne Y. ; Laga, Alvaro C.

Basal cell carcinomas (BCC) are driven primarily by cumulative ultraviolet (UV) radiation exposure resulting in activation of the Hedgehog (Hh) signaling pathway, often as a result of UV-mediated Patched-1 (PTCH1) gene inactivation. Accordingly, BCCs most commonly arise at sun-exposed sites such as the head and neck. Very rarely, BCCs can arise at sun-protected sites such as the genital skin and perianal area. This can pose significant diagnostic challenges not only due to the rarity of BCC at these sites but also due to the potential morphologic overlap with other entities such as basaloid squamous cell carcinoma, trichoblastic carcinoma, and even benign neoplasms such as trichoblastomas. Hh pathway alterations have not yet been described in BCCs arising at genital and perianal sites, and the role of UV radiation is uncertain at these anatomic locations. To address this ambiguity, we report the clinicopathologic features of a cohort of 14 BCCs arising at sun-protected sites (perianal n=7, vulva n=4, scrotum n=3). Furthermore, we use a next-generation DNA sequencing platform to investigate their pathogenesis and compare it to that of a cohort of 8 BCCs arising on sun-exposed skin. We find that BCCs arising on sun-protected sites display a spectrum of morphologic patterns, rarely recur, and do not metastasize. Both sun-protected and sun-exposed BCCs are characterized by recurrent PTCH1 alterations (93% and 100% of cases, respectively), supporting the classification of the tumors arising at sun-protected sites as bona fide BCCs. Notably, in contrast to conventional BCCs, none of the sun-protected BCCs harbored a UV mutation signature, suggesting an alternative mechanism of mutagenesis. Furthermore, the presence of upstream Hh pathway alterations in sun-protected BCCs supports their susceptibility to Hh pathway inhibitors such as vismodegib and sonidegib.

News (Medical) associated with Sonidegib Phosphate

02 Apr 2025

·www.prnewswire.com

Senhwa Biosciences Announces Positive Clinical Data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma

Basal Cell Carcinoma CSR Highlights CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Response: Three patients achieved partial response (PR), while ten patients had stable disease (SD). Tolerability & Disease Control Rate: Shows potential superiority over current first- and second-line therapies. Unmet Medical Need: Enrolled patients with refractory or recurrent disease who had no remaining treatment options. TAIPEI and SAN DIEGO, April 2, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that the completion of Clinical Study Report (CSR) for Phase 1/Dose Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma(BCC), with positive data outcomes. The study included patients who had relapsed after standard therapies and had no other treatment options. Among them, three patients experienced over 30% tumor reduction (PR), and two patients had a progression-free survival (PFS) exceeding 21 months. CX-4945 significantly prolonged survival in advanced cancer patients, marking a major milestone for both the patients and Senhwa. Compared to current first- and second-line therapies, CX-4945 demonstrated superior tolerability and disease control potential. Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company aims to explore further indications and potential as a first-line treatment, offering better options for patients. Clinical Trial Overview The trial enrolled 25 patients with locally advanced BCC (laBCC, 20 patients) and metastatic BCC (mBCC, 5 patients). The primary objective was to determine the recommended Phase 2 dose (RP2D) and optimal dosing regimen for CX-4945. Among 22 patients eligible for efficacy analysis: Three laBCC patients achieved partial response (PR). Ten patients had stable disease (SD), including 2 mBCC and 8 laBCC patients. Disease control rates: mBCC patients: 80% (4 patients with complete/partial response or stable disease). laBCC patients: 65% (11 patients with complete/partial response or stable disease). Further data analysis showed that: Median progression-free survival (PFS): laBCC: 9.2 months mBCC: 3.7 months Median duration of disease control (DDC): laBCC: 10.3 months mBCC: 7.5 months CX-4945 exhibited promising anti-tumor efficacy and disease stabilization potential in this indication. Additionally, CX-4945 has a lower study drug discontinuation rate of 24% due to AEs, compared to first-line treatments including Vismodegib and Sonidegib, suggesting superior tolerability. Future Prospects This trial is particularly noteworthy as it evaluated CX-4945 monotherapy in patients who had already failed first-line HHIs. Notably, 27.3% (6 patients) had also failed second-line PD-1 inhibitors such as Libtayo or Keytruda. Among the enrolled patients, two advanced-stage patients achieved a progression-free survival (PFS) of over 21 months, lasting 653 days and 667 days, respectively. Notably, the primary lesion of the former patient was almost undetectable by visual inspection. Given the significant potential of CX-4945 as a monotherapy, Senhwa is now actively pursuing regional licensing to accelerate commercialization through strategic partnerships, ultimately benefiting more patients. SOURCE Senhwa Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultImmunotherapyPhase 1License out/in

11 Dec 2024

·www.businesswire.com

Genesis Therapeutics Expands Leadership Team with Appointments of Chief Scientific Officer, SVP of Engineering, and Board Chairman

BURLINGAME, Calif.--( BUSINESS WIRE )-- Genesis Therapeutics , a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients, today announced the appointments of three key members during 2024 to its senior leadership team and Board of Directors: Shifeng Pan, Ph.D., as Chief Scientific Officer; Alla Ivanova as Senior Vice President of Engineering; and Paul A. Friedman, M.D., as Chairman of the Board. “ We are thrilled to welcome to our team these exceptional leaders who share belief in our mission and approach to transforming drug discovery with groundbreaking predictive and generative AI technologies,” said Evan Feinberg, Ph.D., founder and CEO of Genesis. “ Their industrial expertise across technology and drug discovery will enable us to further advance our GEMS (Genesis Exploration of Molecular Space) AI platform, expand our therapeutic pipeline, and ultimately create breakthrough treatments for patients suffering from severe diseases.” Shifeng Pan, Ph.D., Chief Scientific Officer: Dr. Pan joined Genesis in April 2024 and oversees R&D activities for Genesis’ pipeline of AI-enabled therapeutics. He brings more than two decades of experience in medicinal chemistry and biopharmaceutical research, including a 22-year career at Novartis, where he served as Head of Discovery Chemistry at the Genomics Institute of the Novartis Research Foundation. At Novartis, he led the discovery of FDA-approved drugs ODOMZO ® , BRAFTOVI ® , and MAYZENT ® , as well as numerous other programs across several therapeutic areas. Dr. Pan joins Genesis from Odyssey Therapeutics, where he was Executive Vice President and Head of Discovery. He earned a doctorate in organic chemistry from New York University. “ Genesis’ AI capabilities enable the discovery of novel and breakthrough molecules, making its platform well-suited to address challenging or historically undruggable targets,” said Dr. Pan. “ It’s an exciting time for the field of AI-enabled drug discovery and our premier team of engineers, chemists, and biologists who are leveraging the GEMS platform to rapidly advance our broad therapeutic pipeline.” Alla Ivanova, Senior Vice President of Engineering: Ms. Ivanova joined Genesis in November 2024 and brings over 25 years of experience driving innovation in software development; spanning data center management, large-scale infrastructure, and high-traffic web applications to cutting-edge AI/ML solutions. She has held executive leadership roles at notable tech companies including Head of Looker Engineering at Google Cloud, VP of Cloud & Data Infrastructure at Atlassian, Head of Core Infrastructure at Uber, Senior Director of Data Platform at Groupon, and Software Engineering Manager at Netflix. Ms. Ivanova earned her master's degree in applied mathematics and computer science from Kazan Federal University. “ At a time when AI is redefining the boundaries of what’s possible in drug discovery, I’m honored to be joining the Genesis team,” said Ms. Ivanova. “ The company’s AI platform, GEMS, has the potential to unlock the promise of computational drug design and discover life-changing medicines for patients. I’m excited to continue advancing transformational AI work, not just for innovation’s sake but to make a meaningful difference in human health – a mission that resonates deeply with me and the future I envision for AI.” Paul A. Friedman, M.D., Chairman of the Board of Directors: Dr. Friedman has served as Chairman of the company’s Board of Directors since April 2024. With decades of experience in biotechnology and drug development, he has held senior leadership roles at notable pharmaceutical companies, including CEO of Madrigal Pharmaceuticals (2016–2023), CEO of Incyte (2001–2014), President of Research and Development at DuPont-Merck Pharmaceutical, President of DuPont Pharmaceuticals Research Laboratories, and Senior Vice President of Merck Research Laboratories. He has also served as a board member for several publicly held pharmaceutical companies, including Incyte and Alexion. A diplomate of the American Board of Internal Medicine and member of the American Society of Clinical Investigation, Dr. Friedman earned his medical degree from Harvard Medical School. " Genesis is in an exciting period of growth following an outstanding Series B fundraise last year and recent collaboration with Gilead, positioning the company well to advance and expand its AI-enabled pipeline to develop breakthrough therapies for patients,” said Dr. Friedman. This expansion of Genesis’ senior leadership team follows the company’s appointments of two industry veterans to its Board of Directors: Vijay Pande, Ph.D., Founding General Partner at Andreessen Horowitz’s (a16z) Bio + Health fund, joined as a Director in 2023, and Mohamed “Sid” Siddeek, Vice President and Head of NVentures, NVIDIA’s venture capital arm, joined as an observer in 2024. About Genesis Therapeutics Genesis Therapeutics is pioneering AI for biotechnology by leveraging its generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space) for small molecule drug discovery. GEMS synthesizes proprietary AI methods, including language models, diffusion models, and physical ML simulations, to generate and optimize molecules for complex targets. Genesis has raised over $300 million from leading life science, tech, and AI-focused investors, and is building a therapeutic pipeline for a variety of high-impact targets. Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. For more information on Genesis, please visit the company’s website at www.genesistherapeutics.ai .

Executive Change

25 Oct 2024

·www.prnewswire.com

Sun Pharma Announces Multiple Data Presentations Highlighting its Dermatology Portfolio to be Featured at the 2024 Fall Clinical Dermatology Conference

Data from a wide range of the Sun Pharma dermatology portfolio, including data on alopecia areata, psoriasis, acne and actinic keratosis products, will be highlighted during the meeting. MUMBAI, India and PRINCETON, N.J., Oct. 25, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced it will present more than a dozen posters at the 44th Annual Fall Clinical Dermatology Conference, being held October 24-27, 2024, in Las Vegas, Nevada. The presentations will include data from across the Sun Pharma dermatology portfolio, including study results for LEQSELVI™ (deuruxolitinib), WINLEVI® (clascoterone), ILUMYA® (tildrakizumab-asmn), ODOMZO® (sonidegib) and LEVULAN® KERASTICK® (aminolevulinic acid HCl) + BLU-U® (blue light photodynamic therapy). "As an organization dedicated to supporting the dermatology community, the Fall Clinical Dermatology Conference offers a vitally important forum to present new data and highlight how Sun's innovative dermatology portfolio can support those living with alopecia areata, psoriasis, acne and other skin-related diseases," said Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Development at Sun Pharma. "We look forward to sharing data from across our portfolio with the dermatology research community and our esteemed industry colleagues." Six abstracts, accepted for poster presentations, will highlight clinical efficacy and safety data of LEQSELVI™ (deuruxolitinib). Approved earlier this year by the U.S. Food and Drug Administration for the treatment of adults with severe alopecia areata, LEQSELVI™ is an oral JAK inhibitor that interrupts the pathways thought to contribute to hair loss in severe AA and delivered statistically significant efficacy at 24 weeks across two Phase 3 clinical trials. LEQSELVI™ data being presented at Fall Clinical showcase pooled long-term results for ongoing clinically meaningful improvements in scalp hair regrowth in adults with alopecia areata. Additionally, two posters will present patient and clinician preferences for the treatment of alopecia areata. The WINLEVI® poster presentations will include new data showing significant reductions in casual facial sebum levels from baseline, stability in the presence of other commonly prescribed acne medications, and efficacy and safety from a pilot study in patients with skin of color. The conference will also feature data from three additional WINLEVI® studies. Sun Pharma will present the following posters at the 2024 Fall Clinical Dermatology Conference: LEQSELVI™ Presentations: Deuruxolitinib results in ongoing clinically meaningful improvements in scalp hair regrowth in adults with alopecia areata: Pooled long-term efficacy and safety data from the open-label extension studies Patient Preferences for the Treatment of Alopecia Areata A Discrete Choice Experiment to Assess Clinician Preferences for the Treatment of Alopecia Optimization of deuruxolitinib dosing in adult patients with alopecia area: Results from a randomized, parallel-group, multicenter Phase 2 trial Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials Improvement in anxiety and depression in adult patients with severe alopecia areata treated with deuruxolitinib: Pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials WINLEVI® Presentations: Clinical evaluation of the sebum reduction induced by clascoterone cream 1%: Week 12 interim analysis Assessment of clascoterone cream 1% levels when layered with other topical acne medications Efficacy and safety of clascoterone cream 1% in patients with acne with skin of color: 16-week interim analysis The efficacy and safety of clascoterone cream 1% for the treatment of acne vulgaris are not dependent on patient age and sex: Results of a post hoc analysis Improvement in skin moisturization and lack of barrier damage with clascoterone cream 1% treatment: Results of a randomized, single-blind, split-face study in acne-prone individuals Comparison of the efficacy of clascoterone vs trifarotene and tazarotene for the treatment of acne vulgaris at Week 12: A systematic review and meta-analysis ILUMYA® Presentation: A systematic literature review and meta-analysis of the real-world effectiveness, quality of life, and safety of tildrakizumab for moderate-to-severe plaque psoriasis ODOMZO® Presentation: Lower rate of discontinuation of sonidegib compared to vismodegib in a real-world analysis of patients with basal cell carcinoma LEVULAN® KERASTICK® + BLU-U® Presentation: Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by blue light in the treatment of facial cutaneous squamous cell carcinoma in situ About Sun Pharmaceutical Industries Limited. (CIN – L24230GJ1993PLC019050) Sun Pharma is the world's leading specialty generics company with a presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. For further information, please visit and follow us on LinkedIn & X (Formerly Twitter). Disclaimer: Statements in this "document" describing Sun Pharma's objectives, projections, estimates, expectations, plans or predictions, industry conditions, or events may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. Sun Pharma does not undertake any obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. SOURCE Sun Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Clinical ResultPhase 2

100 Deals associated with Sonidegib Phosphate

External Link

KEGG	Wiki	ATC	Drug Bank
D10729	Sonidegib Phosphate	L01XX48	DB09143

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Metastatic basal cell carcinoma	Australia	Sun Pharma ANZ Pty Ltd.	10 Aug 2015
Basal Cell Carcinoma	United States	Sun Pharmaceutical Industries Ltd.	24 Jul 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Basal Cell Nevus Syndrome	Phase 3	Belgium	Novartis Pharmaceuticals Corp.	03 Mar 2017
Basal Cell Nevus Syndrome	Phase 3	Canada	Novartis Pharmaceuticals Corp.	03 Mar 2017
Basal Cell Nevus Syndrome	Phase 3	Czechia	Novartis Pharmaceuticals Corp.	03 Mar 2017
Basal Cell Nevus Syndrome	Phase 3	Finland	Novartis Pharmaceuticals Corp.	03 Mar 2017
Basal Cell Nevus Syndrome	Phase 3	Germany	Novartis Pharmaceuticals Corp.	03 Mar 2017
Basal Cell Nevus Syndrome	Phase 3	Greece	Novartis Pharmaceuticals Corp.	03 Mar 2017
Basal Cell Nevus Syndrome	Phase 3	Italy	Novartis Pharmaceuticals Corp.	03 Mar 2017
Basal Cell Nevus Syndrome	Phase 3	Spain	Novartis Pharmaceuticals Corp.	03 Mar 2017
Basal Cell Nevus Syndrome	Phase 3	Switzerland	Novartis Pharmaceuticals Corp.	03 Mar 2017
Basal Cell Nevus Syndrome	Phase 3	United Kingdom	Novartis Pharmaceuticals Corp.	03 Mar 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04066504 (NISSO, Pubmed \| BMC Cancer)	Not Applicable	Basal Cell Carcinoma	321	Sonidegib 200 mg	jfufzugwzb(itriepblnp) = Most TEAEs were ≤ grade 2 and the most common were muscle spasms (43.9%), dysgeusia (37.1%), and alopecia (30.2%) ofxypwplbe (turieviezg ) View more	Positive	14 Nov 2024
BOLT study (EADV2023)	Phase 2	Basal Cell Carcinoma	194	Sonidegib 200 mg daily	krggzerjxx(uxuwunctww) = vnkroqvpfn hvpayvhkgb (xzqpvnodki, 15.1 - NE)	-	11 Oct 2023
WCD2023	Not Applicable	-	-	Sonidegib	erkystpqeq(scghwquvkq) = ockgxhjeay xlmjqcwnfu (ggflomrxgi ) View more	-	05 Jul 2023
NCT04007744 (ASCO 12023 \| ASCO 22023) Manual	Phase 1	HR-positive/HER2-low Solid Tumors \| Non-Small Cell Lung Cancer	33	Sonidegib Phosphate+Pembrolizumab	mphvqyecvt(nqmpvbpvnc) = chfuxpbixo odmoguczez (zjdyaiggyp ) View more	Positive	26 May 2023
VISMONEO (EADV2022)	Not Applicable	Locally Advanced Squamous Cell Carcinoma Neoadjuvant	13	Sonidegib	yqcsfzvegr(gpxrxuirce) = tusvlqjasq nrygbtdvkk (fxorjdbwgl, 6.3 - 27.3) View more	Positive	07 Sep 2022
NCT01327053 (BOLT, Pubmed \| BMC Cancer)	Phase 2	Basal Cell Carcinoma	66	Sonidegib 200 mg	kqihposbmo(eaionabzpv) = ezekieorrh hqiqywseeh (rkduivtzoc ) View more	-	19 Nov 2021
NCT01327053 (BOLT, Pubmed \| Dermatol Ther (Heidelb))	Phase 2	Basal Cell Carcinoma	230	Sonidegib 200 mg	hkrmvwljrs(ajbkypzphj) = dupziawwgb nmbbbvihtf (rvyfysgukw )	-	20 Oct 2021
NCT01787552 (Pubmed \| Blood Adv) Manual	Phase 1/2	Primary Myelofibrosis	50	sonidegib+ruxolitinib	cyscpxmbby(ejgrdjfhut) = at level 2: increased blood creatine phosphokinase (grades 3 and 4, n = 1 each) ssmsgocwdr (hpzforyxmi ) View more	Negative	14 Jul 2020
NCT02086552 (CTgov)	Phase 2	Recurrent Multiple Myeloma \| Refractory Multiple Myeloma	28	Laboratory Biomarker Analysis+Lenalidomide+Sonidegib	mpwzkhuqrn = rjdvtfmoxx uwskcvfajo (qaycuiozlx, vcmxaajtek - tjdjpegqny) View more	-	29 May 2019
NCT02027376 (GEICAM/2012-12 (EDALINE), Pubmed \| Invest New Drugs) Manual	Phase 1	Advanced Triple-Negative Breast Carcinoma triple negative	12	Docetaxel+Sonidegib Phosphate	wugqknubsw(ksjxvxceaw) = sonidegib 800 mg orally q.d. + docetaxel 75 mg/m2 given intravenously on day 1 of 21-day cycles kzuvoahohi (rwwjlfayrg ) View more	Positive	01 Feb 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis